MX2018004868A - Pyrrolidine derivatives. - Google Patents
Pyrrolidine derivatives.Info
- Publication number
- MX2018004868A MX2018004868A MX2018004868A MX2018004868A MX2018004868A MX 2018004868 A MX2018004868 A MX 2018004868A MX 2018004868 A MX2018004868 A MX 2018004868A MX 2018004868 A MX2018004868 A MX 2018004868A MX 2018004868 A MX2018004868 A MX 2018004868A
- Authority
- MX
- Mexico
- Prior art keywords
- acute
- compounds
- well
- disorders
- pyrrolidine derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se proporcionan compuestos de la fórmula I: (ver Fórmula) así como sus sales farmacéuticamente aceptables, en donde los sustituyentes son como los descritos en la descripción. Estos compuestos, y las composiciones farmacéuticas que los contienen, son útiles para el tratamiento o prevención de trastornos mediados por mG1uR5, tales como trastornos neurológicos agudos y/o crónicos, trastornos cognitivos y déficits de memoria, así como dolor agudo y crónico.Compounds of the formula I are provided: (see Formula) as well as their pharmaceutically acceptable salts, wherein the substituents are as described in the description. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment or prevention of disorders mediated by mG1uR5, such as acute and / or chronic neurological disorders, cognitive disorders and memory deficits, as well as acute and chronic pain.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510713865.7A CN106632243B (en) | 2015-10-28 | 2015-10-28 | Pyrrolidin derivatives |
| PCT/CN2016/102946 WO2017071536A1 (en) | 2015-10-28 | 2016-10-21 | Pyrrolidine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018004868A true MX2018004868A (en) | 2018-11-09 |
| MX385587B MX385587B (en) | 2025-03-18 |
Family
ID=58629839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018004868A MX385587B (en) | 2015-10-28 | 2016-10-21 | PYRROLIDINE DERIVATIVES. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10328054B2 (en) |
| EP (1) | EP3371163B1 (en) |
| JP (1) | JP6877771B2 (en) |
| KR (1) | KR102815874B1 (en) |
| CN (2) | CN106632243B (en) |
| AU (1) | AU2016345244B2 (en) |
| BR (1) | BR112018008204B1 (en) |
| CA (1) | CA3000794C (en) |
| DK (1) | DK3371163T3 (en) |
| ES (1) | ES2922978T3 (en) |
| HU (1) | HUE058899T2 (en) |
| IL (1) | IL258517B (en) |
| MX (1) | MX385587B (en) |
| RU (1) | RU2740019C1 (en) |
| TW (1) | TWI725998B (en) |
| WO (1) | WO2017071536A1 (en) |
| ZA (1) | ZA201802235B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE057734T2 (en) | 2013-10-04 | 2022-06-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and their application |
| CN113616656B (en) | 2014-03-19 | 2023-02-17 | 无限药品股份有限公司 | Heterocyclic compounds for the treatment of PI 3K-gamma mediated disorders |
| EP3350183B1 (en) | 2015-09-14 | 2025-04-02 | Twelve Therapeutics, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| CN106632243B (en) * | 2015-10-28 | 2019-03-15 | 华领医药技术（上海）有限公司 | Pyrrolidin derivatives |
| KR102740618B1 (en) * | 2021-11-17 | 2024-12-10 | 유노비아 주식회사 | Preparation method of isoxazole derivatives and intermediates thereof |
| CN119569744B (en) * | 2024-11-19 | 2026-01-02 | 武汉大学人民医院（湖北省人民医院） | Pyranopyridone alkaloids, their preparation methods and applications |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0503646D0 (en) | 2005-02-22 | 2005-03-30 | Novartis Ag | Organic compounds |
| CN101990536B (en) * | 2008-01-18 | 2014-09-03 | 上海靶点药物有限公司 | Pyrollidine-based compounds |
| TW201116532A (en) * | 2009-08-05 | 2011-05-16 | Merz Pharma Gmbh & Co Kgaa | Metabotropic glutamate receptor modulators |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| WO2012152854A1 (en) * | 2011-05-12 | 2012-11-15 | Merz Pharma Gmbh & Co. Kgaa | Metabotropic glutamate receptor modulators |
| UA110862C2 (en) * | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Ethinyl derivatives as allosteric modulators of metabotropic glutamate receptor 5 mglur |
| WO2014124560A1 (en) * | 2013-02-18 | 2014-08-21 | Hua Medicine (Shanghai) Ltd. | Mglur regulators |
| CN106632243B (en) * | 2015-10-28 | 2019-03-15 | 华领医药技术（上海）有限公司 | Pyrrolidin derivatives |
-
2015
- 2015-10-28 CN CN201510713865.7A patent/CN106632243B/en active Active
-
2016
- 2016-10-21 ES ES16858971T patent/ES2922978T3/en active Active
- 2016-10-21 CN CN201680062993.2A patent/CN108349935B/en active Active
- 2016-10-21 US US15/771,920 patent/US10328054B2/en active Active
- 2016-10-21 MX MX2018004868A patent/MX385587B/en unknown
- 2016-10-21 KR KR1020187014851A patent/KR102815874B1/en active Active
- 2016-10-21 RU RU2018119038A patent/RU2740019C1/en active
- 2016-10-21 DK DK16858971.1T patent/DK3371163T3/en active
- 2016-10-21 HU HUE16858971A patent/HUE058899T2/en unknown
- 2016-10-21 JP JP2018541471A patent/JP6877771B2/en active Active
- 2016-10-21 BR BR112018008204-0A patent/BR112018008204B1/en active IP Right Grant
- 2016-10-21 EP EP16858971.1A patent/EP3371163B1/en active Active
- 2016-10-21 CA CA3000794A patent/CA3000794C/en active Active
- 2016-10-21 AU AU2016345244A patent/AU2016345244B2/en active Active
- 2016-10-21 WO PCT/CN2016/102946 patent/WO2017071536A1/en not_active Ceased
- 2016-10-27 TW TW105134694A patent/TWI725998B/en active
-
2018
- 2018-04-05 ZA ZA2018/02235A patent/ZA201802235B/en unknown
- 2018-04-05 IL IL258517A patent/IL258517B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| HK1254456A1 (en) | 2019-07-19 |
| JP2018532778A (en) | 2018-11-08 |
| CA3000794C (en) | 2024-01-16 |
| EP3371163A4 (en) | 2019-05-01 |
| WO2017071536A1 (en) | 2017-05-04 |
| US20180318254A1 (en) | 2018-11-08 |
| TWI725998B (en) | 2021-05-01 |
| KR20180070693A (en) | 2018-06-26 |
| IL258517A (en) | 2018-05-31 |
| CN108349935B (en) | 2021-02-05 |
| MX385587B (en) | 2025-03-18 |
| JP6877771B2 (en) | 2021-05-26 |
| ES2922978T3 (en) | 2022-09-22 |
| IL258517B (en) | 2020-05-31 |
| US10328054B2 (en) | 2019-06-25 |
| BR112018008204A2 (en) | 2018-12-18 |
| DK3371163T3 (en) | 2022-07-04 |
| CN106632243A (en) | 2017-05-10 |
| CN106632243B (en) | 2019-03-15 |
| RU2740019C1 (en) | 2020-12-30 |
| KR102815874B1 (en) | 2025-06-02 |
| BR112018008204B1 (en) | 2023-12-26 |
| HUE058899T2 (en) | 2022-09-28 |
| CN108349935A (en) | 2018-07-31 |
| EP3371163B1 (en) | 2022-03-30 |
| EP3371163A1 (en) | 2018-09-12 |
| CA3000794A1 (en) | 2017-05-04 |
| AU2016345244A1 (en) | 2018-04-26 |
| TW201718542A (en) | 2017-06-01 |
| AU2016345244B2 (en) | 2020-07-09 |
| ZA201802235B (en) | 2019-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201900070A (en) | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | |
| CO2019000386A2 (en) | Heterocyclic compounds as immunomodulators | |
| CL2018001685A1 (en) | Heterocyclic compounds as immuno modulators. | |
| DOP2017000048A (en) | AMINOPIRIMIDINYL COMPOUNDS AS JAK INHIBITORS. | |
| EA201691302A1 (en) | NEW HETEROCYCLIC COMPOUNDS | |
| MX2018003432A (en) | HETEROCICLICAL COMPOUNDS AND USES OF THE SAME. | |
| DOP2016000271A (en) | FUSIONED BICYCLIC HETEROARILO OR ARILO COMPOUNDS | |
| SV2015005066A (en) | BIARIL-AMIDA COMPOUNDS AS CINASA INHIBITORS | |
| UY35663A (en) | DERIVATIVES OF PIPERIDINIL-INDOL AS INHIBITORS OF COMPLEMENT FACTOR B AND USES OF THE SAME | |
| UY35898A (en) | ? SYK INHIBITING COMPOUNDS AND COMPOSITIONS THAT UNDERSTAND THEM ?. | |
| MX2018004868A (en) | Pyrrolidine derivatives. | |
| UY36654A (en) | AZABENZIMIDAZOLES WITH AMPA RECEPTOR MODULATING PROPERTIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| DOP2015000201A (en) | AZABENCIMIDAZOL COMPOUNDS AS INHIBITORS OF PDEN4 ISOENZIMAS FOR THE TREATMENT OF THE CNS AND OTHER DISORDERS | |
| MX2021005052A (en) | Oxysterols and methods of use thereof. | |
| UY35625A (en) | TETRAHYDROCARBAZOL AND CARBAZOL CARBOXAMIDA COMPOUNDS REPLACED AS QUINASA INHIBITORS | |
| UY36875A (en) | BROMODOMINIUM INHIBITING COMPOSITIONS FOR THE TREATMENT OF VARIOUS DISEASES | |
| EA201691600A1 (en) | DIHYDROPYRIDINOUS INHIBITORS MGAT2 FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | |
| MX2022006862A (en) | DUAL MAGL AND FAAH INHIBITORS. | |
| CL2017000040A1 (en) | Aldosterone synthase inhibitors. | |
| CO2017000011A2 (en) | Quinolizinone derivatives as pi3k inhibitors | |
| CU20160166A7 (en) | COMPOUNDS DERIVED FROM N- (1,5-DIMETIL-3-OXO-2,3-DIHIDRO-1H-PIRAZOL-4-IL) -4-METHYL-5-ISOXAZOL-3-CARBOXAMIDE AS SELECTIVE INHIBITORS OF SMURF-1 | |
| CL2018001631A1 (en) | Alkyl dihydroquinolinsulfonamide compounds | |
| CL2017000827A1 (en) | Aldosterone synthase inhibitors | |
| MX379454B (en) | FLUOROINDOL DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC M1 RECEPTOR. | |
| CL2018003109A1 (en) | Polymorphic forms of 3- [2-butyl-1- (2-diethylamino-ethyl-1h-benzoimidazol-5-yl] -n-hydroxy-acrylamide and their uses. |